Interim Clinical Policy: Puberty suppressing hormones for children and adolescents who have gender incongruence/dysphoria

Overview

NHS England commissions gender incongruence and dysphoria services and the purpose of this consultation is to seek views on a proposed interim clinical policy on puberty suppressing hormones (sometimes referred to as ‘puberty blockers’ or ‘hormone blockers’) for children and adolescents who have gender incongruence or dysphoria.

The policy proposition is that puberty suppressing hormones are not recommended to be available as a routine commissioning option for the treatment of children and adolescents who have gender incongruence or dysphoria.

This public consultation will run for 90 days from 3 August to 1 November 2023.

At the end of the consultation period, all feedback will be considered before the interim clinical policy is published.

We recommend that you read this consultation guide alongside the other documents published as part of the consultation.

Supporting documentation

• Interim policy
• Engagement report
• Equalities and health inequalities impact assessment
• Post-engagement evidence report
• Literature surveillance report
• NICE evidence reivew